OncoC4 ImmunoPharma Group consists of six companies located in China, the United States, and Australia, primarily focusing on the research and development of innovative immunotherapeutic drugs for the treatment of malignant tumors and inflammatory diseases. The scientific team includes Professor Yang Liu, an internationally renowned immunologist and Fellow of the American Association for the Advancement of Science (AAAS).With the rapid rise of innovative drugs in China, Professor Liu and his partners established Guangzhou AcroImmune BioTech. Co., Ltd. in 2018. In March 2022, Guangzhou AcroImmune BioTech. Co., Ltd. signed an agreement with the Jiangning High-Tech Zone to establish  AcroImmune Biopharmaceutical Co., Ltd. as the Chinese R&D center and future industrialization base. The company is dedicated to developing innovative immunotherapeutic drugs, focusing on the immune treatment of malignant tumors and inflammatory diseases, aiming to provide more treatment options for clinical patients.

AcroImmune Biopharmaceutical Co., Ltd. is located within the Ruihong Cell and Gene Industrial Park. The company is constructing a research and development center and pilot production workshop across three floors, totaling 6,000 square meters, to accelerate the development and approval process of innovative drug products.

In March 2024, the OncoC4 ImmunoPharma Large Molecule Drug Research Center and the OncoC4 ImmunoPharma Antibody-Drug Conjugate Innovation Center were inaugurated in the Jiangning High-Tech Zone of Nanjing. The newly renovated research laboratories, pilot production workshops, and quality control laboratories are now operational, with researchers already on-site and conducting project experiments. Multiple products are currently under development.